A public offering of Series B convertible preferred stock and stock purchase warrants has brought in $18.1 million for EnteroMedics. The proceeds will be used to continue the company's commercialization activities, as well as to for general corporate functions and clinical and product development.
A $17.5 million all-cash agreement has been reached by Roka Bioscience to sell substantially all of its assets to newly created Institute for Environmental Health subsidiary Rokabio. The deal, which comes as Roka's first step in liquidation, requires a $2.5 million milestone payment from Roka in conformity with a license deal and provision of transition services to IEH through the end of the year.
Private placements of Series B convertible preferred stock and common stock could pull in $4.3 million for DarioHealth. Plans for the proceeds from the offerings, which are expected to close by Tuesday, have not yet been disclosed by the company.
Monroe, Conn.-based Elidah is looking to obtain up to $2 million in additional proceeds after securing up to $750,000 in pledged investment from the state-backed Connecticut Innovations venture fund last month. The company plans to use the proceeds to market its Elitone wearable device for treating women with stress urinary incontinence if it secures approval from the FDA.
An Absolute Reports analysis predicts the worldwide minimally invasive spine surgery market will see a compound annual growth rate of 7.57% through 2021 because of an increasing incidence of spinal disorder. Key market players include DePuy Synthes, Stryker, Medtronic, Zimmer Biomet and NuVasive.
Myriad Genetics obtained positive coverage decisions from Anthem and Medicare contractor Palmetto GBA for its EndoPredict breast cancer recurrence test. Myriad estimated that upon full implementation of the decisions, 90% of breast cancer patients will be covered for the test.
Preliminary data from a 458-patient study showed Endologix's AFX and AFX2 endografts demonstrated an 84.7% rate of freedom from aneurysm-related complications, compared with 82% for other bifurcated aortic endografts. Further randomization in the study will be stopped by the company based on the number of additional participants needed for proving superiority, while five-year follow-up of current participants will be continued.
European regulators gave HeartSciences CE mark approval for its MyoVista high sensitivity electrocardiograph testing device, a technology that uses Continuous Wavelet Transform to measure cardiac energy per heartbeat. The device, which is a combination of traditional 12-lead resting ECG tracings, ECG interpretive analysis and informatics, has also been launched by the company in Europe.
The FDA granted Globus Medical clearance to market its robotic guidance and navigation platform, Excelsius GPS, which is designed for use in traditional and minimally invasive orthopedic and neurosurgical procedures. The system facilitates accurate screw placement in spine and orthopedic surgery and can function with intraoperative CT, preoperative CT and fluoroscopic imaging modalities.
Nov. 14-15 | Washington, D.C. From products to consumers to regulation and new media -- we're gathering industry practitioners to take a deep dive on the opportunities and challenges of product advertising. This annual conference will teach you how to communicate your value without overstepping legal and regulatory boundaries. FDA staff, medical technology company leaders, legal experts and public affairs professionals will lead discussions. Learn more.
The AdvaMed Purchasing Group is a new member-only benefit that helps companies purchase the very best goods and services from nationally recognized suppliers at the very best cost, using a trusted and proven vetting system and the collective purchasing power of our membership. Participation is free for AdvaMed members, and there are no minimum commitments. Get started today.